vosaroxin
Small moleculeexperimental
Vosaroxin is a topoisomerase II inhibitor causing site-selective DNA damage. It is under phase III clinical trial investigation for acute myelogenous leukemia (AML) and ovarian cancer sponsored by Sunesis. — Wikipedia
Clinical trial activity
16 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
10
Phase 3
2
Phase 4
0
Earliest trial started Jun 1, 2004 (NCT00091585)
Timeline
Indications
Studied for
- Acute Disease · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Ovarian Epithelial · Phase 2
- Carcinoma, Small Cell · Phase 2
- Leukemia · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 1
- Leukemia, Myeloid, Acute · Phase 3
- Myelodysplastic Syndromes · Phase 2
- Neoplasms · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Sarcoma, Myeloid · Phase 2
- Small Cell Lung Carcinoma · Phase 2
Mechanism of action
- DNAINHIBITOR
DNA inhibitor
First-in-class topoisomerase II poison and inhibitor that intercalates DNA and induces site-selective DNA DSB, G2 arrest, and apoptosis
- DNA topoisomerase IIINHIBITOR
DNA topoisomerase II inhibitor
First-in-class topoisomerase II poison and inhibitor that intercalates DNA and induces site-selective DNA DSB, G2 arrest, and apoptosis
Chemistry & pharmacology
Loading structure…
SMILES
CN[C@H]1CN(c2ccc3c(=O)c(C(=O)O)cn(-c4nccs4)c3n2)C[C@@H]1OC- Mol. weight
- 401.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaVosaroxin ↗
- ChEMBLCHEMBL68117 ↗
Also known as
- 1,4-dihydro-7-(3-methoxy-4-methylamino-1-pyrrolidinyl)-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
- ag7352
- ag 7352
- ag-7352
- sns-595
- sns-595
- sns-595
- sns-595
- voreloxin
- voreloxin
- voreloxin
- voreloxin
- voreloxin
- vosaroxin
- vosaroxin
- vosaroxin
- vosaroxin
- vosaroxin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03338348 | Phase 2 | Apr 19, 2018 | Sunesis Pharmaceuticals, University of Ulm |
| NCT02658487 | Phase 2 | Mar 1, 2016 | National Cancer Institute (NCI), Vanderbilt University |
| NCT02485353 | N/A | Oct 1, 2015 | Indiana University |
| NCT02416388 | Phase 2/Phase 3 (Phase 3) | Jan 1, 2015 | University of Antwerp |
| NCT01913951 | Phase 1 | Nov 22, 2013 | Washington University in St. Louis |
| NCT01980056 | Phase 1/Phase 2 (Phase 2) | Oct 25, 2013 | Cornell University, Sunesis Pharmaceuticals |
| NCT01893320 | Phase 1/Phase 2 (Phase 2) | Jul 18, 2013 | Sunesis Pharmaceuticals, University of Texas at Houston |
| NCT01191801 | Phase 3 | Dec 17, 2010 | Sunesis Pharmaceuticals |
| NCT00607997 | Phase 2 | Apr 1, 2008 | Sunesis Pharmaceuticals |
| NCT00541866 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2007 | Sunesis Pharmaceuticals |
| NCT00408603 | Phase 2 | Nov 1, 2006 | Sunesis Pharmaceuticals |
| NCT00298896 | Phase 2 | Feb 1, 2006 | Sunesis Pharmaceuticals |
| NCT00246662 | Phase 1 | Nov 14, 2005 | Sunesis Pharmaceuticals |
| NCT00252382 | Phase 2 | Nov 1, 2005 | Sunesis Pharmaceuticals |
| NCT00094159 | Phase 1 | Oct 1, 2004 | Sunesis Pharmaceuticals |
| NCT00091585 | Phase 1 | Jun 1, 2004 | Sunesis Pharmaceuticals |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sunesis Pharmaceuticals | For profit | 12 | 9 | 3 | 2004 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Indiana University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2016 |
| University of Antwerp | Academic/Hospital | 1 | 1 | 1 | 2015 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2013 |
| University of Ulm | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Vanderbilt University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2013 |
9 organizations
Page 1 / 1